FULC Live signals | Maximize Profits with Getagraph.com

SELL 104059 min ago

@ $8.91

Issued: 14 Feb 2024 @ 14:26

Return: -19.87%

Previous signal: Feb 13 - 15:22

Previous signal: Buy

Return: -1.22 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	261 291
Average Volume	639 874
Market Cap	442.22M
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.440 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.49
ATR14	$0.00900 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Horn Patrick Taylor	Buy	400 000	Stock Option (right to buy)
2024-03-18	Horn Patrick Taylor	Sell	0	No securities are beneficially owned
2024-03-08	Tourangeau Greg	Sell	4 884	Common Stock
2024-03-04	Sapir Alex	Buy	43 360	Common Stock
2024-01-26	Tourangeau Greg	Buy	83 820	Stock Option (right to buy)

INSIDER POWER
20.77
Last 98 transactions
Buy: 8 691 029 \| Sell: 9 119 346

Volume Correlation

Long: -0.05 (neutral)

Short: 0.68 (moderate)

Signal:(49.35) Neutral

Fulcrum Therapeutics Inc Correlation

10 Most Positive Correlations
ABST	0.942
SRTS	0.94
MULN	0.929
VNET	0.928
CNDT	0.919
EGAN	0.917
SABRP	0.916
SABR	0.91
DOYU	0.91
PASG	0.907

10 Most Negative Correlations
RDUS	-0.927
XOG	-0.9
TYHT	-0.895
EPZM	-0.881
OPCH	-0.871
SYKE	-0.868
HSTM	-0.864
CNCE	-0.856
CRWD	-0.848
ICON	-0.846

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fulcrum Therapeutics Inc Correlation - Currency/Commodity

0.72
( moderate )

0.52
( weak )

0.00
( neutral )

-0.39
( neutral )

Fulcrum Therapeutics Inc Financials

Annual	2023
Revenue:	$2.81M
Gross Profit:	$633 000 (22.57 %)
EPS:	$-1.590

FY	2023
Revenue:	$2.81M
Gross Profit:	$633 000 (22.57 %)
EPS:	$-1.590

FY	2022
Revenue:	$6.34M
Gross Profit:	$3.93M (61.94 %)
EPS:	$-2.35

FY	2021
Revenue:	$19.16M
Gross Profit:	$19.16M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.